Evidence map›Paper›PMID 32121666›Full record

ArticleVaccines2020

Advanced Safety and Genetic Stability in Mice of a Novel DNA-Launched Venezuelan Equine Encephalitis Virus Vaccine with Rearranged Structural Genes.

Dylan M Johnson, Kevin J Sokoloski, Jenny D Jokinen, Tia L Pfeffer, Yong-Kyu Chu, Robert S Adcock, Donghoon Chung, Irina Tretyakova, Peter Pushko, Igor S Lukashevich

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Dylan M JohnsonDepartment of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0002-3630-0588
Kevin J SokoloskiDepartment of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0002-8728-2340
Jenny D JokinenDepartment of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Tia L PfefferCenter for Predictive Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Yong-Kyu ChuCenter for Predictive Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Robert S AdcockCenter for Predictive Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Donghoon ChungDepartment of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Irina TretyakovaMedigen, Inc., Frederick, MD 21701, USA.
Peter PushkoMedigen, Inc., Frederick, MD 21701, USA.
Igor S LukashevichCenter for Predictive Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0001-6523-5116
University of Louisville · USMedigen (United States) · US

Funding

WKU Lead Faculty AwardP20GM103436 · NIGMS · UNIVERSITY OF LOUISVILLE · PI ERIC C ROUCHKA · 2012 to 2026
$60.1M
PILOT PROJECT PROGRAMP30GM106396 · NIGMS · UNIVERSITY OF LOUISVILLE · PI MILLER, DONALD M. · 2013 to 2017
$5.4M
Novel DNA-Launched Attenuated Vaccine for VEE Virus SBIR Phase IIR44AI094863 · NIAID · MEDIGEN, INC. · PI PUSHKO, PETER M. · 2016 to 2017
$1.6M
Novel DNA-Launched Attenuated Vaccine for VEE VirusR43AI094863 · NIAID · MEDIGEN, INC. · PI PUSHKO, PETER M. · 2011 to 2012
$600k
National Institute of Allergy and Infectious Diseases AI094863NIAID NIH HHS R43 AI094863NIGMS NIH HHS P20 GM103436NIGMS NIH HHS P30 GM106396
6 · The paper itself

Abstract

The safety and genetic stability of V4020, a novel Venezuelan Equine Encephalitis Virus (VEEV) vaccine based on the investigational VEEV TC-83 strain, was evaluated in mice. V4020 was generated from infectious DNA, contains a stabilizing mutation in the E2-120 glycoprotein, and includes rearrangement of structural genes. After intracranial inoculation (IC), replication of V4020 was more attenuated than TC-83, as documented by low clinical scores, inflammation, viral load in brain, and earlier viral clearance. During the first 9 days post-inoculation (DPI), genes involved in inflammation, cytokine signaling, adaptive immune responses, and apoptosis were upregulated in both groups. However, the magnitude of upregulation was greater in TC-83 than V4020 mice, and this pattern persisted till 13 DPI, while V4020 gene expression profiles declined to mock-infected levels. In addition, genetic markers of macrophages, DCs, and microglia were strongly upregulated in TC-83 mice. During five serial passages in the brain, less severe clinical manifestations and a lower viral load were observed in V4020 mice and all animals survived. In contrast, 13.3% of mice met euthanasia criteria during the passages in TC-83 group. At 2 DPI, RNA-Seq analysis of brain tissues revealed that V4020 mice had lower rates of mutations throughout five passages. A higher synonymous mutation ratio was observed in the nsP4 (RdRP) gene of TC-83 compared to V4020 mice. At 2 DPI, both viruses induced different expression profiles of host genes involved in neuro-regeneration. Taken together, these results provide evidence for the improved safety and genetic stability of the experimental V4020 VEEV vaccine in a murine model.

Indexed as

DNA vaccinegene rearrangementgenetic stabilitylive-attenuated vaccinereversionsafetyVenezuelan equine encephalitis virus

Identifiers

PMID32121666
PMCPMC7157698
OpenAlexW3010474308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.